Induction of Autoantibodies during Prolonged Treatment with Infliximab

Journal of Rheumatology

Volumn 30, Issue 12, 2003, Pages 2557-2562

  Louis, Mariam ^a,b   Rauch, Joyce ^a,b   Armstrong, Mary ^a   Fitzcharles, Mary Ann ^a,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Department of Medicine ^*  (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Autoantibodies; Infliximab

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN; DNA ANTIBODY; HYDROXYCHLOROQUINE; INFLIXIMAB; LA ANTIBODY; METHOTREXATE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SALAZOSULFAPYRIDINE; SMOOTH MUSCLE ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; PRIORITY JOURNAL; RHEUMATIC DISEASE; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0348109373     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Elliot MJ, Maini RN, Feldmann M, et al. Randomized double blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
2. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
3. Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
4. Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR. Infliximab and methotrexate in the treatment of RA. N Engl J Med 2000;343:1594-602.
5. Brandt J, Haibel H, Sieper J, Redding J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001;44:2936-7.
6. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-a monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
7. Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
8. Phillips K, Husni ME, Karlson E, Coblyn JS. Experience with etanercept in an academic medical center: Are the infection rates increased? Arthritis Care Res 2002;47:17-21.
9. Fitzcharles M, Clayton D, Ménard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol 2002;12:2525-30.
10. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;12:2521-4.
11. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
12. Casciola C, Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30.
13. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:148-9.
14. James JA, Harley JB. B-cell epitope spreading in autoimmunity. Immunol Rev 1998;164:185-200.
15. Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, De Marchi G, Fabris M. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology Oxford 2002;41:1109-12.
16. Jonsdottir T, Harju A, van Vollenhoven A, Klareskog L. van Vollenhoven R. Treatment with TNF-antagonists is associated with an increasing frequency of anticardiolipin antibodies (ACLA) - ACLA positivity predicts worse clinical outcome [abstract]. Arthritis Rheum 2002;46 Suppl:S573.
17. Antivalle M, Marrazza M, Randisi G, et al. Long term treatment of rheumatoid arthritis with infliximab: Efficacy, side effects and autoantibody induction [abstract]. Arthritis Rheum 2002:46 Suppl:S534.
18. Bingham S, Barcelos A, Buch M, Lindsay S, Emery P. Induction of serological lupus in patients on leflunomide and infliximab [abstract]. Arthritis Rheum 2002;46 Suppl:S168.
19. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753-5.